418 related articles for article (PubMed ID: 10369066)
1. Antibody dependent cellular phagocytosis (ADCP) and antibody dependent cellular cytotoxicity (ADCC) of breast cancer cells mediated by bispecific antibody, MDX-210.
Watanabe M; Wallace PK; Keler T; Deo YM; Akewanlop C; Hayes DF
Breast Cancer Res Treat; 1999 Feb; 53(3):199-207. PubMed ID: 10369066
[TBL] [Abstract][Full Text] [Related]
2. Phagocytosis of breast cancer cells mediated by anti-MUC-1 monoclonal antibody, DF3, and its bispecific antibody.
Akewanlop C; Watanabe M; Singh B; Walker M; Kufe DW; Hayes DF
Cancer Res; 2001 May; 61(10):4061-5. PubMed ID: 11358826
[TBL] [Abstract][Full Text] [Related]
3. Bispecific antibody-targeted phagocytosis of HER-2/neu expressing tumor cells by myeloid cells activated in vivo.
Wallace PK; Kaufman PA; Lewis LD; Keler T; Givan AL; Fisher JL; Waugh MG; Wahner AE; Guyre PM; Fanger MW; Ernstoff MS
J Immunol Methods; 2001 Feb; 248(1-2):167-82. PubMed ID: 11223077
[TBL] [Abstract][Full Text] [Related]
4. G-CSF-stimulated PMN in immunotherapy of breast cancer with a bispecific antibody to Fc gamma RI and to HER-2/neu (MDX-210).
Repp R; Valerius T; Wieland G; Becker W; Steininger H; Deo Y; Helm G; Gramatzki M; Van de Winkel JG; Lang N
J Hematother; 1995 Oct; 4(5):415-21. PubMed ID: 8581378
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetic-pharmacodynamic relationships of the bispecific antibody MDX-H210 when administered in combination with interferon gamma: a multiple-dose phase-I study in patients with advanced cancer which overexpresses HER-2/neu.
Lewis LD; Cole BF; Wallace PK; Fisher JL; Waugh M; Guyre PM; Fanger MW; Curnow RT; Kaufman PA; Ernstoff MS
J Immunol Methods; 2001 Feb; 248(1-2):149-65. PubMed ID: 11223076
[TBL] [Abstract][Full Text] [Related]
6. Phase I clinical trial of the bispecific antibody MDX-H210 (anti-FcgammaRI x anti-HER-2/neu) in combination with Filgrastim (G-CSF) for treatment of advanced breast cancer.
Repp R; van Ojik HH; Valerius T; Groenewegen G; Wieland G; Oetzel C; Stockmeyer B; Becker W; Eisenhut M; Steininger H; Deo YM; Blijham GH; Kalden JR; van de Winkel JG; Gramatzki M
Br J Cancer; 2003 Dec; 89(12):2234-43. PubMed ID: 14676800
[TBL] [Abstract][Full Text] [Related]
7. Bispecific antibody-dependent cellular cytotoxicity of HER2/neu-overexpressing tumor cells by Fc gamma receptor type I-expressing effector cells.
Keler T; Graziano RF; Mandal A; Wallace PK; Fisher J; Guyre PM; Fanger MW; Deo YM
Cancer Res; 1997 Sep; 57(18):4008-14. PubMed ID: 9307286
[TBL] [Abstract][Full Text] [Related]
8. Differential effect of cytokine treatment on Fc alpha receptor I- and Fc gamma receptor I-mediated tumor cytotoxicity by monocyte-derived macrophages.
Keler T; Wallace PK; Vitale LA; Russoniello C; Sundarapandiyan K; Graziano RF; Deo YM
J Immunol; 2000 Jun; 164(11):5746-52. PubMed ID: 10820252
[TBL] [Abstract][Full Text] [Related]
9. Preclinical studies with Fc(gamma)R bispecific antibodies and granulocyte colony-stimulating factor-primed neutrophils as effector cells against HER-2/neu overexpressing breast cancer.
Stockmeyer B; Valerius T; Repp R; Heijnen IA; Bühring HJ; Deo YM; Kalden JR; Gramatzki M; van de Winkel JG
Cancer Res; 1997 Feb; 57(4):696-701. PubMed ID: 9044847
[TBL] [Abstract][Full Text] [Related]
10. Monocyte-mediated lysis of acute myeloid leukemia cells in the presence of the bispecific antibody 251 x 22 (anti-CD33 x anti-CD64).
Chen J; Zhou JH; Ball ED
Clin Cancer Res; 1995 Nov; 1(11):1319-25. PubMed ID: 9815927
[TBL] [Abstract][Full Text] [Related]
11. Generation of HER-2/neu-specific cytotoxic neutrophils in vivo: efficient arming of neutrophils by combined administration of granulocyte colony-stimulating factor and Fcgamma receptor I bispecific antibodies.
Heijnen IA; Rijks LJ; Schiel A; Stockmeyer B; van Ojik HH; Dechant M; Valerius T; Keler T; Tutt AL; Glennie MJ; van Royen EA; Capel PJ; van de Winkel JG
J Immunol; 1997 Dec; 159(11):5629-39. PubMed ID: 9548506
[TBL] [Abstract][Full Text] [Related]
12. Clinical experience with CD64-directed immunotherapy. An overview.
Curnow RT
Cancer Immunol Immunother; 1997; 45(3-4):210-5. PubMed ID: 9435876
[TBL] [Abstract][Full Text] [Related]
13. A phase I study of a HER2/neu bispecific antibody with granulocyte-colony-stimulating factor in patients with metastatic breast cancer that overexpresses HER2/neu.
Pullarkat V; Deo Y; Link J; Spears L; Marty V; Curnow R; Groshen S; Gee C; Weber JS
Cancer Immunol Immunother; 1999 Apr; 48(1):9-21. PubMed ID: 10235484
[TBL] [Abstract][Full Text] [Related]
14. Initial trial of bispecific antibody-mediated immunotherapy of CD15-bearing tumors: cytotoxicity of human tumor cells using a bispecific antibody comprised of anti-CD15 (MoAb PM81) and anti-CD64/Fc gamma RI (MoAb 32).
Ball ED; Guyre PM; Mills L; Fisher J; Dinces NB; Fanger MW
J Hematother; 1992; 1(1):85-94. PubMed ID: 1365020
[TBL] [Abstract][Full Text] [Related]
15. Trastuzumab mediates antibody-dependent cell-mediated cytotoxicity and phagocytosis to the same extent in both adjuvant and metastatic HER2/neu breast cancer patients.
Petricevic B; Laengle J; Singer J; Sachet M; Fazekas J; Steger G; Bartsch R; Jensen-Jarolim E; Bergmann M
J Transl Med; 2013 Dec; 11():307. PubMed ID: 24330813
[TBL] [Abstract][Full Text] [Related]
16. Clinical trials of bispecific antibody MDX-210 in women with advanced breast or ovarian cancer that overexpresses HER-2/neu.
Valone FH; Kaufman PA; Guyre PM; Lewis LD; Memoli V; Ernstoff MS; Wells W; Barth R; Deo Y; Fisher J
J Hematother; 1995 Oct; 4(5):471-5. PubMed ID: 8581387
[TBL] [Abstract][Full Text] [Related]
17. CpG-A and B oligodeoxynucleotides enhance the efficacy of antibody therapy by activating different effector cell populations.
van Ojik HH; Bevaart L; Dahle CE; Bakker A; Jansen MJ; van Vugt MJ; van de Winkel JG; Weiner GJ
Cancer Res; 2003 Sep; 63(17):5595-600. PubMed ID: 14500400
[TBL] [Abstract][Full Text] [Related]
18. Enhancement of antibody-dependent cell-mediated cytotoxicity by endowing IgG with FcαRI (CD89) binding.
Borrok MJ; Luheshi NM; Beyaz N; Davies GC; Legg JW; Wu H; Dall'Acqua WF; Tsui P
MAbs; 2015; 7(4):743-51. PubMed ID: 25970007
[TBL] [Abstract][Full Text] [Related]
19. Production of macrophage-activated killer cells for targeting of glioblastoma cells with bispecific antibody to FcgammaRI and the epidermal growth factor receptor.
Wallace PK; Romet-Lemonne JL; Chokri M; Kasper LH; Fanger MW; Fadul CE
Cancer Immunol Immunother; 2000 Nov; 49(9):493-503. PubMed ID: 11092616
[TBL] [Abstract][Full Text] [Related]
20. Gamma-interferon inhibits Fc receptor II-mediated phagocytosis of tumor cells by human macrophages.
Backman KA; Guyre PM
Cancer Res; 1994 May; 54(9):2456-61. PubMed ID: 7909275
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
